Capricor Therapeutics Temettüler ve Geri Alımlar
Temettü kriter kontrolleri 0/6
Capricor Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.
Anahtar bilgiler
n/a
Temettü verimi
-49.3%
Geri Alım Getirisi
| Toplam Hissedar Getirisi | -49.3% |
| Gelecekteki Temettü Verimi | n/a |
| Temettü Büyümesi | n/a |
| Bir sonraki temettü ödeme tarihi | n/a |
| Eski temettü tarihi | n/a |
| Hisse başına temettü | n/a |
| Ödeme oranı | n/a |
Son temettü ve geri alım güncellemeleri
Güncelleme yok
Recent updates
Anlatı Güncellemesi • Sep 08
CAPR: November FDA Decision On Refined Upper Limb Indication Will Drive Upside Potential
Capricor Therapeutics' updated analyst price target of $54, up from $28, reflects a shift toward higher implied valuation as analysts factor in the FDA's acceptance of deramiocel's major amendment, the extended action date to November 22, and the possibility of a refined upper limb function indication despite ongoing regulatory risk flagged in recent research. Analyst Commentary Recent research on Capricor Therapeutics highlights a wide range of views, but several bullish analysts point to a clearer regulatory path for deramiocel and a reset in valuation expectations after new FDA interactions.Seeking Alpha • Sep 03
Capricor: Downgrade To Hold On Deramiocel PDUFA Extension And DMD Change
Summary Capricor Therapeutics, Inc. is downgraded from Buy to Hold due to regulatory setbacks for deramiocel in Duchenne Muscular Dystrophy [DMD]. An FDA Advisory Committee voted primarily against deramiocel's approval for DMD cardiomyopathy, increasing regulatory risk despite prior positive Phase 3 HOPE-3 data. CAPR is now pursuing FDA review for deramiocel in a new proposed indication—upper limb function in DMD—with a revised PDUFA date of November 22, 2026. While the primary endpoint was met and new data submitted for upper limb function, the major amendment classification and extended review timeline heighten uncertainty and increases risk. Read the full article on Seeking AlphaAnlatı Güncellemesi • Aug 25
CAPR: November FDA Decision On Refined Duchenne Indication Will Drive Upside Potential
Capricor Therapeutics’ analyst fair value estimate has reset from $63.00 to $28.00 as analysts factor in a higher discount rate, a lower assumed future P/E multiple, and continued regulatory uncertainty around deramiocel, despite the new HOPE-3 open-label extension data. Analyst Commentary Recent Street research around Capricor Therapeutics highlights a sharp divergence in views, with most firms reacting cautiously to the negative advisory committee outcome for deramiocel and the extended regulatory timeline, while a smaller group of bullish analysts sees potential valuation upside if the refined indication and new data package gain traction with regulators.
Anlatı Güncellemesi • Aug 11
CAPR: Post AdCom Regulatory Outcome Will Drive 2026 Upside Potential
Capricor Therapeutics now carries a sharply reduced analyst price target of about $4.38, down from roughly $49.44, as analysts factor in the negative deramiocel AdCom vote, heightened FDA approval concerns, higher perceived risk, and lower projected profitability and P/E multiples. Analyst Commentary Recent research on Capricor Therapeutics has shifted sharply after the deramiocel advisory committee outcome, with most firms now focused on regulatory risk, legal overhangs, and reduced earnings potential.Anlatı Güncellemesi • Jul 27
CAPR: July FDA Panel Vote Will Determine Bullish 2026 Approval Path
Capricor Therapeutics' analyst fair value estimate has been reduced from $54.67 to $49.44, as analysts factor in sharply lower price targets following critical FDA briefing documents on deramiocel, multiple downgrades to Neutral ratings, and increased concern that current data and statistical protocols may not support approval in its present form. Analyst Commentary Recent Street research on Capricor Therapeutics highlights a sharp reassessment of risk around deramiocel ahead of the upcoming FDA advisory committee meeting, with price targets and ratings moving in response to concerns over data integrity, statistical methods, and regulatory pushback.
Yeni Anlatı • Jul 12
The Exosome Pioneer: Why Capricor (CAPR) is Poised for an August FDA Breakthrough
Prologue: Witnessing the Exosome Revolution in Clinical Practice As a veterinarian actively running a clinic in 2026, I have seen firsthand the disruptive power of exosome technology. Last year, I introduced an 'exosome ice-needling injection machine' at my hospital to treat some of the most stubborn conditions in small animals.Anlatı Güncellemesi • Jun 15
CAPR: August FDA Decision On Duchenne Therapy Will Drive Long Term Upside Potential
Capricor Therapeutics' analyst price target has been cut by $5, to $38 from $43, as analysts factor in the removal of an expected $80 million milestone payment linked to the NS Pharma dispute and a later modeled U.S. launch for Deramiocel. Analyst Commentary Bullish analysts are recalibrating their models around the NS Pharma dispute and timing of the Deramiocel U.S. launch, yet some still see meaningful potential tied to upcoming regulatory and monetization events.
Anlatı Güncellemesi • Jun 01
CAPR: FDA Decision And HOPE-3 Data Will Drive Bullish Repricing
Analysts have trimmed their average price target on Capricor Therapeutics by about $1.60 to roughly $39.40. This reflects adjustments for the removed $80m milestone and a later modeled Deramiocel U.S. launch, while still factoring in upcoming FDA decisions and related catalysts.Anlatı Güncellemesi • May 15
CAPR: August PDUFA Decision Will Shape Duchenne Treatment Adoption Outlook
Narrative Update: Capricor Therapeutics Analyst Price Target Shift The analyst price target for Capricor Therapeutics has been reduced by $5 to $38, as analysts factor in the removal of an expected $80 million milestone payment and a later modeled U.S. launch for Deramiocel following the company’s legal action against NS Pharma. Analyst Commentary Recent Street research around Capricor Therapeutics has shifted from purely optimistic toward a more balanced stance, as bullish analysts factor in both regulatory progress for Deramiocel and the impact of the company’s legal action against NS Pharma.Anlatı Güncellemesi • Apr 29
CAPR: August PDUFA Cardiac Data Will Drive Bullish 2026 Approval Setup
Narrative Update: Capricor Therapeutics The updated analyst price target framework for Capricor Therapeutics moves from a prior fair value of $50.80 to $54.67. This reflects analysts' use of higher projected revenue growth, wider profit margins and a higher future P/E multiple following recent positive deramiocel data, FDA review progress and a series of target increases across the Street.Anlatı Güncellemesi • Apr 15
CAPR: August PDUFA Decision Will Drive Bullish Duchenne Thesis
Analysts have lifted their average price targets on Capricor Therapeutics into a $41 to $63 range, supported by recent FDA progress on deramiocel for Duchenne muscular dystrophy, additional positive Phase 3 HOPE-3 data, and updated cash and review timelines that feed into modest tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions in the valuation model. Analyst Commentary Bullish analysts are largely framing recent volatility in Capricor Therapeutics as a short-term shakeout rather than a shift in the long-term story.Anlatı Güncellemesi • Apr 01
CAPR: August PDUFA And HOPE 3 Readout Will Shape Bullish Case
Analysts have lifted their blended price target on Capricor Therapeutics to $63, supported by higher targets from several firms. These firms point to recent FDA milestones for deramiocel in Duchenne muscular dystrophy, additional Phase 3 HOPE-3 data, and updated PDUFA timing as key drivers behind their refreshed assumptions.Anlatı Güncellemesi • Mar 18
CAPR: August PDUFA Decision And HOPE 3 Data Will Drive Bullish Outlook
Narrative Update on Capricor Therapeutics The analyst fair value estimate for Capricor Therapeutics has moved from $62.00 to $63.00, reflecting updated Street research that points to higher price targets tied to recent FDA progress for deramiocel in Duchenne muscular dystrophy and supportive Phase 3 HOPE-3 data. Analyst Commentary Recent Street research has been broadly constructive on Capricor Therapeutics, with bullish analysts highlighting regulatory milestones for deramiocel in Duchenne muscular dystrophy and updated Phase 3 HOPE-3 data as key drivers behind their views.Anlatı Güncellemesi • Mar 03
CAPR: HOPE 3 Data And BLA Resubmission Will Drive Bullish 2026 Approval Path
Analysts now place a slightly higher implied value on Capricor Therapeutics, with their updated price target moving to $62.00. This is supported by modest tweaks to the discount rate, revenue growth assumptions, and long-term profit margin and P/E inputs.Anlatı Güncellemesi • Feb 17
CAPR: HOPE-3 Regulatory Progress And Capital Raise Will Drive Bullish Repricing
Analysts have kept their $41.00 price target for Capricor Therapeutics unchanged, citing only minor model adjustments such as slightly different discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Capricor provided a regulatory update on its Biologics License Application for Deramiocel in Duchenne muscular dystrophy, with the FDA requesting the full Phase 3 HOPE-3 clinical study report and supporting data to address a Complete Response Letter, without asking for additional clinical studies or new patient data.Anlatı Güncellemesi • Feb 03
CAPR: Phase 3 Duchenne Cardiac Results Will Shape Bullish 2026 Approval Path
Narrative Update The analyst price target for Capricor Therapeutics has moved from about US$44.56 to US$50.80, with analysts pointing to expectations around Phase 3 HOPE-3 data for Deramiocel in Duchenne muscular dystrophy cardiomyopathy and updated modeling assumptions as key drivers of the change. Analyst Commentary Recent Street research points to a change in how some analysts are framing risk and potential reward around Capricor Therapeutics, especially with Phase 3 HOPE-3 data for Deramiocel in Duchenne muscular dystrophy cardiomyopathy expected in Q4.Anlatı Güncellemesi • Jan 20
CAPR: HOPE 3 Cardiac Outcome Data Will Shape Bullish Mid 2026 Approval Path
The analyst price target for Capricor Therapeutics has increased from $12 to $13, as analysts incorporate updated assumptions for Deramiocel approval in Duchenne muscular dystrophy cardiomyopathy and anticipated Phase 3 HOPE-3 cardiac outcome data. Analyst Commentary Bullish analysts are framing the price target move to US$13 as a reflection of updated expectations around Deramiocel in Duchenne muscular dystrophy cardiomyopathy rather than a broad shift in the overall story.Anlatı Güncellemesi • Jan 06
CAPR: HOPE-3 Duchenne Cardiac Data Will Drive Bullish Repricing
Analysts have lifted their fair value estimate for Capricor Therapeutics from $12.00 to $41.00 per share, citing updated assumptions around Deramiocel approval prospects in Duchenne muscular dystrophy cardiomyopathy, following recent Street research and price target revisions. Analyst Commentary Recent Street commentary around Capricor Therapeutics has centered on expectations for Deramiocel in Duchenne muscular dystrophy cardiomyopathy, with valuation work closely tied to regulatory outcomes and clinical readouts for the Phase 3 HOPE-3 trial anticipated in Q4.Anlatı Güncellemesi • Dec 19
CAPR: Mid 2026 Approval Path Will Drive HOPE 3 Cardiac Catalyst Narrative
Analysts have sharply increased their price target for Capricor Therapeutics, effectively more than doubling fair value from approximately $29 to about $62. They cite higher projected revenue growth, a dramatic improvement in long term profit margins, a more normalized future earnings multiple, and growing confidence that positive HOPE-3 data could support regulatory flexibility and keep a potential Deramiocel approval on track for mid 2026.Anlatı Güncellemesi • Dec 05
CAPR: Phase 3 Duchenne Cardiac Data Will Drive 2026 Approval Hopes
Analysts have sharply raised their price target on Capricor Therapeutics, with the modeled fair value estimate climbing from about $20.60 to roughly $44.56 per share. They cite stronger expected revenue growth, significantly improved profit margins, and increasing confidence that positive HOPE-3 Phase 3 data could support Deramiocel approval for Duchenne muscular dystrophy cardiomyopathy on an accelerated mid 2026 timeline.Analiz Makalesi • Nov 05
We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analiz Makalesi • Sep 09
Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
To the annoyance of some shareholders, Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shares are down a considerable 30...Analiz Makalesi • Jun 24
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
To the annoyance of some shareholders, Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shares are down a considerable 25...Analiz Makalesi • May 16
Here's Why We Think Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Compensation Looks Fair
Key Insights Capricor Therapeutics to hold its Annual General Meeting on 22nd of May CEO Linda Marbán's total...Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: CAPR şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.
Büyüyen Temettü: CAPR şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.
Piyasaya Karşı Temettü Getirisi
| Capricor Therapeutics Piyasaya Karşı Temettü Getirisi |
|---|
| Segment | Temettü Verimi |
|---|---|
| Şirket (CAPR) | n/a |
| Pazarın Alt %25'i (US) | 1.4% |
| Pazarın En İyi %25'i (US) | 4.1% |
| Sektör Ortalaması (Biotechs) | 2.2% |
| Analist tahmini (CAPR) (3 yıla kadar) | n/a |
Önemli Temettü: CAPR şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.
Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CAPR şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: CAPR şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: CAPR herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.
Güçlü temettü ödeyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/15 04:07 |
| Gün Sonu Hisse Fiyatı | 2026/09/15 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Capricor Therapeutics, Inc. 10 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Matthew Venezia | Alliance Global Partners |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Kristen Kluska | Cantor Fitzgerald & Co. |